Krystal Biotech’s (KRYS) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Krystal Biotech (NASDAQ:KRYS) in a research report sent to investors on Tuesday,Benzinga reports. The brokerage currently has a $221.00 price objective on the stock.

KRYS has been the subject of several other reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Krystal Biotech in a research note on Thursday, August 29th. Citigroup raised their target price on Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Evercore ISI lifted their price target on shares of Krystal Biotech from $201.00 to $206.00 and gave the stock an “outperform” rating in a research report on Monday, August 12th. Stifel Nicolaus raised their price objective on Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a research note on Wednesday, September 11th. Finally, William Blair raised Krystal Biotech to a “strong-buy” rating in a research note on Friday, August 30th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $202.86.

Krystal Biotech Stock Down 7.3 %

NASDAQ:KRYS opened at $173.40 on Tuesday. The firm has a market cap of $4.99 billion, a PE ratio of 97.97 and a beta of 0.80. Krystal Biotech has a 12 month low of $107.50 and a 12 month high of $219.34. The company’s 50-day moving average price is $181.59 and its two-hundred day moving average price is $184.95.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, November 4th. The company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.84 by $0.07. The business had revenue of $83.84 million for the quarter, compared to analyst estimates of $82.94 million. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. Krystal Biotech’s revenue for the quarter was up 879.9% on a year-over-year basis. During the same period in the prior year, the company earned ($0.67) EPS. On average, research analysts expect that Krystal Biotech will post 2.97 EPS for the current fiscal year.

Institutional Investors Weigh In On Krystal Biotech

Several institutional investors have recently bought and sold shares of the company. AlphaMark Advisors LLC bought a new stake in shares of Krystal Biotech in the second quarter worth $353,000. Blue Trust Inc. raised its holdings in Krystal Biotech by 2,328.6% during the second quarter. Blue Trust Inc. now owns 170 shares of the company’s stock worth $30,000 after acquiring an additional 163 shares in the last quarter. Nisa Investment Advisors LLC boosted its position in Krystal Biotech by 11.1% during the second quarter. Nisa Investment Advisors LLC now owns 940 shares of the company’s stock valued at $173,000 after purchasing an additional 94 shares during the last quarter. Louisiana State Employees Retirement System bought a new stake in shares of Krystal Biotech during the 2nd quarter worth approximately $2,296,000. Finally, EFG Asset Management North America Corp. boosted its holdings in shares of Krystal Biotech by 0.5% in the 2nd quarter. EFG Asset Management North America Corp. now owns 12,555 shares of the company’s stock valued at $2,308,000 after buying an additional 60 shares during the last quarter. Institutional investors own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).